Millennium Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Millennium Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#207 of 15,742 sponsors by registered trial count).
Millennium Pharmaceuticals: 135 sponsored US clinical trials, none currently recruiting.
Millennium Pharmaceuticals sponsors 135 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 119 completed. 17 of these trials are in Phase 3-4 (later-stage) and 117 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lymphoma, with 3 trials.
Top-decile sponsor footprint
Millennium Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#207 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
119 of 135 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
135 total, page 3 of 3
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
NCT00783718
Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer
NCT00773929
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
NCT00783692
Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
NCT00715208
Study of MLN8237 in Participants With Advanced Hematological Malignancies
NCT00697346
Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma
NCT00722488
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT00722137
Study of MLN4924 in Adult Patients With Nonhematologic Malignancies
NCT00677170
Safety Study of TAK-700 in Subjects With Prostate Cancer.
NCT00569153
A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma
NCT00636792
Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma
NCT00631631
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients
NCT00507442
A Safety and Pharmacokinetic Study of TAK-285 in Patients With Advanced Cancer
NCT00535522
Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone
NCT00507416
A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors
NCT00500903
Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT00312845
A Study of MLN8054 in Patients With Advanced Solid Tumors
NCT00249301
A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer
NCT00283634
Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis
NCT00298766
VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features
NCT00117351
MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia
NCT00274248
VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma
NCT00111319
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
NCT00085696
MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer
NCT00070837
VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
NCT00063713
Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
NCT00051974
Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma
NCT00051987
Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer
NCT00064610
A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer
NCT00052000
PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT00048230
Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)
NCT00064584
A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039
NCT00063726
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
NCT00257114
Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade
NCT00129207
Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.
NCT00298779
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 86 |
| Phase 2 | 31 |
| Phase 3 | 16 |
| Phase 4 | 1 |
Therapeutic Areas
How the Millennium Pharmaceuticals early-phase archive is shaped
135 indexed studies, none listed as recruiting (0% open); 119 completed (88%).
Phase mix: 17 late (III/IV) vs 117 early (I/II) (early-phase heavy).
Top condition: Lymphoma (3 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Millennium Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 135 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Millennium Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 135 archived trials
- The Miriam Hospital · 136 trials · 11% recruiting
- George Washington University · 133 trials · 18% recruiting
- Shirley Ryan AbilityLab · 138 trials · 26% recruiting
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · 138 trials · 3% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Millennium Pharmaceuticals page
135 registered trials is a research-attention snapshot, not an endorsement of Millennium Pharmaceuticals or any single study.
- None of Millennium Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Lymphoma is the condition Millennium Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Millennium Pharmaceuticals pipeline card: 135 registered trials from official public datasets.Report a data error.